Supporting Information

for

2,2':6,2"-Terpyridine meets 2,6-*bis*(1*H*-1,2,3-triazol-4-yl)pyridine: Tuning the electropical properties of ruthenium(II) complexes

Benjamin Schulze,^{a,b} Christian Friebe,^{a,b} Martin D. Hager,^b Andreas Winter,^b Richard Hoogenboom,^b Helmar Görls^c and Ulrich S. Schubert ^{a,b}*

^a Laboratory of Organic and Macromolecular Chemistry, Friedrich-Schiller-University Jena, Humboldtstr. 10, 07743 Jena, Germany

^b Laboratory for Macromolecular Chemistry and Nanoscience, Eindhoven University of Technology, PO Box 513, 5600 MB Eindhoven, The Netherlands E-Mail: <u>u.s.schubert@tue.nl</u>; <u>www.schubert-group.com</u>

^c Laboratory of Inorganic and Analytic Chemistry, Friedrich-Schiller-University Jena, Lessing-Str. 8, 07743 Jena, Germany.

Table of contents:

Experimental section	pp	2 – 14
X-ray crystallographic data	pp	15 – 16
¹ H and ¹³ C NMR spectra	pp	17 – 30
¹ H- ¹ H gCOSY NMR spectra	pp	31 – 34
MALDI-ToF MS spectra	pp	35 – 41

Experimental Section

Instrumentation

The 1D (¹H and ¹³C) and 2D NMR (gCOSY) spectra were recorded in deuterated solvents (Cambridge Isotope Laboratories Inc.) at 25 °C on a Varian Mercury 400 MHz instrument and are reported in ppm vs. TMS as internal standard. Matrix-assisted laser desorptionionization time-of-flight mass spectrometry (MALDI-ToF MS) was performed on a Voyager-DE PRO biospectrometry workstation (Applied Biosystems) time-of-flight mass spectrometer, with dithranol as matrix. Elemental analyses were obtained on a EuroVector EuroEA3000 elemental analyser for CHNS-O. UV/vis spectra were measured on a Perkin-Elmer Lambda-45 spectrometer, photoluminescence (PL) spectra were recorded on a Perkin-Elmer LS50B luminescence spectrometer. Absolute quantum yields were evaluated on a Hamamatsu Photonic Multi-Channel Analyzer C10027. For these three techniques a concentration of 10⁻⁶ M in degassed acetonitrile (1 cm cuvette) at 25 °C was used. Low temperature photoluminescence experiments were performed in dilute *n*-butyronitrile solutions on a Edinburgh Instruments FS 920 fluorescence spectrometer. Electrochemical experiments were carried out using an Autolab PGSTAT30 potentiostat at a scan rate of 100 mV/s. For this, a standard three-electrode configuration was used, with a platinum disk working electrode, a platinum-rod auxillary electrode and an Ag/AgCl-reference electrode. Ferrocene was added at the end of each experiment as an internal standard. The potentials are quoted vs. the Fc/Fc^+ couple. The solvent was CH_2Cl_2 , containing tetra-*n*-butylammonium hexafluorophosphate (*n*-Bu₄NPF₆, 0.1 M).

General Methods

All reagents were purchased from commercial sources and used without further purification unless specified. The solvents were received from Biosolve and were dried and distilled according to standard procedures. The synthesis of the precursor complexe $Ru(DMSO)_4Cl_2$,¹ the *mono*-terpyridine complexes $Ru(R^2-tpy)Cl_3$ ($R^2 = H$, 4-Br-C₆H₄)² and the homoleptic complex [$Ru(R^2-tpy)_2$](PF_6)₂ (7, $R_2 = H$)^{2a} was carried out according to literature procedures.

¹ E. Duliere, M. Devillers, J. Marchand-Brynaert, *Organometallics* **2003**, *22*, 804.

² (a) A. Winter, J. Hummel, N. Risch, *J. Org. Chem.* **2006**, *71*, 4862. (b) O. Schmelz, M. Rehahn, *e-Polymers* **2002**, 47.

Chromatographic separations were performed on silica gel (SiO₂ 60, 0.040–0.063 mm, Merck KGaA) and aluminium oxide (neutral, 0.063–0.200 mm, Macherey & Nagel). Preparative layer chromatography (PLC) was performed on silica gel (SiO₂ 60 on 20×20 cm glass plates, 1 mm layer thickness, Merck). Preparative size exclusion chromatography was performed on BioRad S-X3 beads swollen with CH₂Cl₂.

Safety Comment

Sodium azide is very toxic, personal protection precautions should be taken. As low molecular weight organic azides are potential explosives, care must be taken during their handling. Generally, when the total number of carbon (N_C) plus oxygen (N_O) atoms is less than the total numbers of nitrogen atoms (N_N) by a ratio of three, *i.e.* (N_C + N_O)/N_N \leq 3, the compound is considered as an explosive hazard. Therefore, the compounds were prepared prior to use and used immediately.

General procedure for the Click reaction with aliphatic azides

A suspension of sodium azide (1.2 eq.) and an alkyl bromide (1 eq.) in ethanol/water (8 mL, 2:1 ratio) in a 20 mL microwave vail equipped with a magnetic stirrerwas heated under microwave irradiation at 125 °C for 1 h. The formation of the alkyl azide was monitored by GC-MS. Subsequently, aqueous solutions of $CuSO_4 \times 5 H_2O$ (46 mg, 10 mol-%) and sodium ascorbate (360 mg, 100 mol-%), additional ethanol (5 mL) and 2,6-diethynylpyridine (1 eq.) were added. The reaction mixture was then heated under microwave irradiation at 100 °C for 1 h, whereupon a precipitate was formed. The precipitation was completed by adding water (10 mL). After filtration and thoroughly washing with water (200 mL), the precipitate was dissolved in CH_2Cl_2 and dried over Na_2SO_4 . The solvent was removed *in vacuo* and the crude product was purified using column chromatography (alumina, $CH_2Cl_2/EtOAc$ as eluent). When applicable, deviations from this general protocol are given below.³

³ (a) V. V. Rostovtsev, L. G. Green, V. V. Fokin, K. B. Sharpless, *Angew. Chem. Int. Ed.*, **2002**, *41*, 2596; T. R. Chan, R. Hilgraf, K. B. Sharpless, V. V. Fokin, *Org. Lett.*, **2004**, *6*, 2853.

2,6-Bis(1-decyl-1H-1,2,3-triazol-4-yl)pyridine, (tripy, $R^1 = C_{10}H_{21}$)



Following the general procedure, sodium azide (184 mg, 2.83 mmol), 1-bromodecane (0.49 mL, 522 mg, 2.36 mmol), $CuSO_4 \times 5 H_2O$ (39 mg, 0.16 mmol), sodium ascorbate (312 mg, 1.57 mmol) and 2,6-diethynylpyridine (100 mg, 0.79 mmol) in DMSO (15 mL) were reacted to yield the desired product as a white solid (369 mg, 95%) after column chromatography (alumina, CH₂Cl₂/EtOAc as eluent).

¹H NMR (400 MHz, CD₂Cl₂): δ = 8.21 (s, 2H, *H*^{5,5''}), 8.06 (d, ³*J* = 7.6 Hz, 2H, *H*^{3',5'}), 7.87 (t, ³*J* = 7.6 Hz, 1H, *H*^{4'}), 4.42 (t, ³*J* = 7.2 Hz, 4H, *H*^{alkyl}), 1.97 (m_c, 4H, *H*^{alkyl}), 1.40–1.25 (m, 28H, *H*^{alkyl}), 0.88 (t, ³*J* = 6.8 Hz, 6H, *H*^{alkyl}) ppm. ¹³C NMR (100 MHz, CD₂Cl₂): δ = 150.3, 148.1, 137.6, 121.9, 118.8, 50.5, 31.8, 30.2, 29.5, 29.4, 29.2, 29.0, 26.4, 22.6, 13.8 ppm. MS (MALDI-TOF, dithranol): *m*/*z* = 494.59 ([M + H]⁺). Elem. anal. calcd. for C₂₉H₄₇N₇ (493.73): C, 70.55%; H, 9.59%; N, 19,86%; found: C, 70.42%; H, 9.80%; N, 19.85%. UV-vis (CH₂Cl₂): λ_{max} (ε/L·mol⁻¹·cm⁻¹) = 303 (10,000) nm.

2,6-Bis(11-undecanol-1-yl-1H-1,2,3-triazol-4-yl)pyridine, (tripy, $R^1 = C_{11}H_{22}OH$)



Following the general procedure, sodium azide (184 mg, 2.83 mmol), 11-bromo-1-undecanol (593 mg, 2.36 mmol), CuSO₄ × 5 H₂O (25 mg, 0.16 mmol), sodium ascorbate (312 mg, 1.57 mmol) and 2,6-diethynylpyridine (100 mg, 0.79 mmol) were reacted at room temperature for 24 h. Due to the decreased solubility of the product, a modified workup was employed: After precipitation of the crude product with water (10 mL) and subsequent filtration, washing thoroughly with water (200 mL) and acetone (3 × 10 mL), the remaining copper salts were removed by refluxing the crude product with an excess of hydroxyethylenediaminetriacetic acid (HEDTA) in dichloromethane/methanol (25 mL, 2:1 ratio) for 2 h. The solution was concentrated *in vacuo* and water (20 mL) was added. The precipitate was filtered and

susequently washed thoroughly with water (25 mL), acetone (2 mL) and diethyl ether (5 mL) to afford the desired product as a white powder (297 mg, 68%).

¹H NMR (400 MHz, CD₂Cl₂): δ = 8.20 (s, 2H, H^{5,5''}), 8.06 (d, ³J = 8 Hz, 2H, H^{3',5'}), 7.87 (t, ³J = 8 Hz, 1H, H^{4'}), 4.43 (t, ³J = 7.2 Hz, 4H, H^{alkyl}), 3.58 (m_c, 4H, H^{alkyl}), 1.99 (m_c, 4H, H^{alkyl}), 1.53 (br s, 2H, H^{OH}), 1.38–1.30 (m, 32H, H^{alkyl}) ppm. A ¹³C NMR spectrum was not measured due to the low solubility. MS (MALDI-TOF, dithranol): *m/z* = 554.37 ([M + H]⁺). Elem. anal. calcd. for C₃₁H₅₁N₇O₂ (553.78): C, 67.23%; H, 9.28%; N, 17.7%; found: C, 67.37%; H, 9.53%; N, 17.52%. UV-vis (CH₂Cl₂): λ_{max} (ε/L·mol⁻¹·cm⁻¹) = 303 (8,000) nm.

2,6-Bis(1-(10-decenyl)-1H-1,2,3-triazol-4-yl)pyridine (tripy, $R^1 = C_8 H_{16} CH = CH_2$)



Following the general procedure, sodium azide (184 mg, 2.83 mmol), 10-bromo-1-decene (0.47 mL, 517 mg, 2.36 mmol), CuSO₄ × 5 H₂O (39 mg, 0.16 mmol), sodium ascorbate (312 mg, 1.57 mmol) and 2,6-diethynylpyridine (100 mg, 1.57 mmol) were reacted at room temperature for 18 h to yield the desired product as a white solid (218 mg, 56%) after gel filtration (alumina, dichloromethane) and size exclusion chromatography (Bio-Beads SX-8, CH₂Cl₂ as eluent).

¹H NMR (400 MHz, CD₂Cl₂): $\delta = 8.26$ (s, 2H, $H^{5.5''}$), 8.08 (d, ³*J* = 8.0 Hz, 2H, $H^{3',5'}$), 7.87 (t, ³*J* = 8.0 Hz, 1H, $H^{4'}$), 5.87–5.77 (m, 2H, H^{olefin}), 5.02–4.91 (m, 4H, H^{olefin}), 4.38 (t, ³*J* = 7.2 Hz, 4H, N-CH₂), 2.04 (m_c, CH₂-CH=CH₂, 4H), 1.92 (m_c, 4H, N-CH₂-CH₂), 1.40–1.29 (m, 20H, H^{alkyl}) ppm. ¹³C NMR (100 MHz, CD₂Cl₂): $\delta = 150.3$, 148.1, 139.2, 137.7, 122.0, 118.8, 113.9, 50.4, 33.7, 30.2, 29.2, 29.0, 28.9, 28.8, 26.4 ppm. MS (MALDI-TOF, dithranol): m/z =490.19 ([M + H]⁺). Elem. anal. calcd. for C₂₉H₄₃N₇ (489.70): C, 71.13%; H, 8.85%; N, 20.02%; found: C, 71.08%; H, 9.01%; N, 20.04%. UV-vis (CH₂Cl₂): λ_{max} (ε /L·mol⁻¹·cm⁻¹) = 302 (11,000), 240 (30,500) nm. 2,6-Bis(1-(4-^tbutyl)benzyl-1H-1,2,3-triazol-4-yl)pyridine (tripy, $R^1 = 4$ -^tBu-C₆H₄-CH₂)



Following the general procedure, sodium azide (184 mg, 2.83 mmol), 4-*t*butyl-benzylbromide (0.43 mL, 536 mg, 2.36 mmol), CuSO₄ × 5 H₂O (39 mg, 0.16 mmol), sodium ascorbate (312 mg, 1.57 mmol) and 2,6-diethynylpyridine (100 mg, 1.57 mmol) were reacted in to yield the desired product as a white solid (367 mg, 92%) after column chromatography (alumina, CH₂Cl₂, gradient with EtOAc as eluent).

¹H NMR (400 MHz, CD₂Cl₂): δ = 8.10 (s, 2H, H^{5,5}''), 8.05 (d, ³J = 8 Hz, 2H, H^{3',5'}), 7.86 (t, ³J = 8 Hz, 1H, H^{4'}), 7,42 (d, ³J = 8.4 Hz, 2H, H^{AA'/BB'}), 7.27 (d, ³J = 8.4 Hz, 2H, H^{BB'/AA'}), 5.55 (s, 4H, CH₂), 1.32 (s, 18H, CH₃) ppm. ¹³C NMR (100 MHz, CH₂Cl₂): δ = 151.9, 150.1, 148.5, 137.6, 131.9, 127.8, 126.0, 122.0, 118.9, ~52 (with solvent), 34.5, 31.0 ppm. MS (MALDI-TOF, dithranol): *m/z* = 506.18 ([M + H]⁺). Elem. anal. calcd. for C₃₁H₃₅N₇ (505.66): C, 73.63%; H, 6.98%; N, 19.39%; found: C, 73.46%; H, 6.86%; N, 19.34%. UV-vis (CH₂Cl₂): λ_{max} (ε/L·mol⁻¹·cm⁻¹) = 303 (10,000) nm.

2,6-Bis(1-(4-methoxyphenyl)-1H-1,2,3-triazol-4-yl)pyridine, (tripy, $R^1 = 4$ -MeO-C₆H₄)



A 50 mL two-neck round bottom flask was equipped with a magnetic stirrer, an argon inlet and a reflux condenser and was loaded with ethanol/water (15 mL, 7:3 ratio), 4-bromoanisole (0.3 mL, 442 mg, 2.36 mmol, 3 equiv.), CuI (45 mg, 0.24 mmol, 10 mol-%), sodium ascorbate (23 mg, 0.12 mmol, 5 mol-%), N,N'-dimethylethylendiamine (0.04 mL, 31 mg, 0.354 mmol, 15 mol-%) and sodium azide (307 mg, 4.72 mmol).⁴ Stirring at room

⁴ C.-Z. Tao, X. Cui, J. Li, A.-X. Liu, L. Liu, Q.-X. Guo, *Tetrahedron Lett.* 2007, 48, 3525.

temperature under argon for 30 min resulted in a blue solution. After refluxing the reaction micture under argon for 2 h, further sodium ascorbate (23 mg) and 2,6-diethynylpyridine (100 mg, 0.79 mmol) were added. The reaction mixture was refluxed for 4 h and then stirred at room temperature for 12 h. The workup (see the General Procedure above), followed by gel filtration (silica, $CH_2Cl_2/EtOAC$ (3:1 ratio) as eluent) and reprecipitation into diethyl ether yielded the desired product (215 mg, 62%).

¹H NMR (400 MHz, CDCl₃): δ = 8.58 (s, 2H, $H^{5,5''}$), 8.19 (d, ³*J* = 7.6 Hz, 2H, $H^{3',5'}$), 7.92 (t, ³*J* = 8 Hz, 1H, $H^{4'}$), 7.72 (d, ³*J* = 8.8 Hz, 2H, $H^{AA'/BB'}$), 7.04 (d, ³*J* = 8.8 Hz, 2H, $H^{BB'/AA'}$), 3.88 (s, 6H, H^{methoxy}) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 160.0, 149.5, 148.0, 138.4, 130.4, 122.2, 120.7, 119.9, 114.8, 55.7 ppm. MS (MALDI-TOF, dithranol): *m/z* 426.29 ([M + H]⁺). Elem. anal. calcd. for C₂₉H₁₉N₇O₂ (425.44): C, 64.93%; H, 4.50%; N, 23.05%; found: C, 65.02%; H, 4.70%; N, 23.18%. UV-vis (CH₂Cl₂): λ_{max} (ε/L·mol⁻¹·cm⁻¹) = 303 (8,000) nm.

2,6-Bis(1-(naphth-1-yl)-1H-1,2,3-triazol-4-yl)pyridine (tripy, R^1 = naphth-1-yl)



1-Naphthylboronic acid (406 mg, 2.36 mmol, 3 equiv.) and sodium azide (184 mg, 2.83 mmol, 3.6 equiv.) were dissolved in methanol (15 mL). After addition of $CuSO_4 \times 5 H_2O$ (38 mg, 0.24 mmol) the resulting brown solution was stirred at room temperature for 12 h with the flask open to the air. The obtained green solution containing the 1-azidonaphthalene was transferred into a 20 mL microwave vail, water (5 mL), an aqueous solution of sodium ascorbate (474 mg, 2.39 mmol) and 2,6-diethynylpyridine (100 mg, 0.79 mmol) were added and the mixture was heated under microwave irradiation at 100 °C for 2 h. Subsequently, aqueous solutions of $CuSO_4 \times 5 H_2O$ (25 mg, 0.16 mmol) and sodium ascorbate (312 mg, 1.57 mmol) were added and the mixture was heated further under microwave irradiation at 100 °C for 2 h. After the usual workup (see general procedure for the click reaction with aliphatic azides) gel filtration (alumina, EtOAc as eluent), column chromatography (alumina, CH₂Cl₂, gradient with EtOAc as eluent) and precipitation with pentane yielded the product as an off-white solid (226 mg, 62%).

¹H NMR (400 MHz, CDCl₃): δ = 8.57 (s, 2H, H^{5,5}, 8.29 (d, ³J = 8 Hz, 2H, H^{3',5'}), 7.99–7.91 (m, 5H, H^{4',naphthyl}), 7.70 (d, ³J = 8.4 Hz, 2H, H^{naphthyl}), 7.61-7.48 (m, 8H, H^{naphthyl}) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 150.0, 148.3, 138.0, 134.1, 134.0, 130.5, 128.4, 128.3, 127.9, 127.1, 125.0, 123.5, 122.3, 119.7 ppm. MS (MALDI-TOF, dithranol): *m*/*z* = 612.25 ([M + H]⁺). Elem. anal. calcd. for C₂₉H₁₉N₇ (465.51): C, 74.82%; H, 4.11%; N, 21.06%; found: C, 74.73%; H, 4.26%; N, 21.32%. UV-vis (CH₂Cl₂): λ_{max} (ε/L·mol⁻¹·cm⁻¹) = 294 (22,000) nm.

 $[Ru(R^{1}-tripy)_{2}](PF_{6})_{2} \quad (R^{1} = C_{10}H_{21}): Bis[2,6-bis(1-decyl-1H-1,2,3-triazol-4-yl)pyridine]$ ruthenium(II) hexafluorophosphate (8)



A 100 mL two-neck round bottom flask with a magnetic stirrer and a reflux condenser was securated three times. Degassed methanol (5 mL) and ethylene glycol (10 mL) were added. In the counterflow of argon, Ru(DMSO)₄Cl₂ (38 mg, 0.08 mmol)⁵ and a concentrated solution of \mathbf{R}^1 -tripy ($\mathbf{R}^1 = \mathbf{C}_{10}\mathbf{H}_{21}$, 85 mg, 0.17 mmol) in degassed acetone were added. The suspension was refluxed under argon for 2.5 h. After cooling to room temperature, water (15 mL) and then an excess of NH₄PF₆ (100 mg) was added. The formed yellow precipitate was filtered off, thoroughly washed with water (10 mL), dissolved in CH₂Cl₂ and dried over Na₂SO₄. The solution was concentrated *in vacuo* and the crude product was purified by size exclusion column chromatography (BioBeads SX-3, CH₂Cl₂ as eluent) to yield **8** as a yellow powder (89 mg, 75%).

¹H NMR (400 MHz, d₆-acetone): $\delta = 9.18$ (s, 4H, $H^{5,5''}$), 8.50–8.41 (m, 6H, $H^{3',4',5'}$), 4.40 (t, ³J = 7.4 Hz, 8H, H^{alkyl}), 1.77 (m, 8H, H^{alkyl}), 1.30–1.00 (m, 56H, H^{alkyl}), 0.86 (t, ³J = 7.0 Hz, 12H, H^{alkyl}) ppm. ¹³C NMR (100 MHz, CD₃CN): $\delta = 150.7$, 149.4, 137.7, 125.2, 119.8, 52.1, 31.6, 29.2, 29.1, 29.0, 28.9, 28.3, 25.5, 22.4, 13.4 ppm. MS (MALDI-TOF, dithranol): m/z =1233.59 ([M - PF₆]⁺). Elem. anal. calcd. for C₅₈H₉₄F₁₂N₁₄P₂Ru (1378.46): C, 50.54%; H, 6.87%; N, 14.23%; found: C, 50.50%; H, 6.91%; N, 13.94%. UV-vis (CH₃CN): λ_{max} (ε/L·mol⁻¹·cm⁻¹) = 394 (15,500), 285 (60,500), 255 (27,000), 226 (45,500) nm.

General procedure for the synthesis of the complexes $[(R^2-tpy)Ru(tripy-R^1)](PF_6)_2$

To a suspension of $(R^2$ -tpy)RuCl₃ (1 equiv.)² and **R¹-tripy** (1 equiv.) in methanol (15 mL) *N*-ethyl morpholine (10 drops) was added and the reaction mixture was stirred under reflux for 24 h. The mixture was filtered hot and then an excess of NH₄PF₆ (100 mg) was added. After stirring for 30 min, water (10 mL) was added and the formed precipitate was filtered off and washed thoroughly with water (10 mL). The precipitate was dissolved in CH₂Cl₂ and the solution evaporated after drying over Na₂SO₄ to give the desired complex. When applicable, deviations from this general protocol are given below.

 $[(R^2-tpy)Ru(tripy-R^1)](PF_6)_2$ $(R^1 = C_{10}H_{21}, R^2 = H)$: [2,6-Bis(1-decyl-1H-1,2,3-triazol-4yl)pyridine] [2,2':6',2''-terpyridine] ruthenium(II) hexafluorophosphate (1)



Following the general procedure, $(R^2-tpy)RuCl_3$ ($R^2 = H$,^{2a} 44 mg, 0.1 mmol) and **R¹-tripy** ($R^1 = C_{10}H_{21}$, 49 mg (0.1 mmol) were reacted to yield **1** (91 mg, 81%) as an orange-red solid after reprecipitation into diethyl ether.

¹H NMR (400 MHz, CD₃CN): δ = 8.68 (s, 2H, $H^{5a,5^{\circ}a}$), 8.64 (d, ³*J* = 8 Hz, 2H, $H^{3^{\circ},5^{\circ}}$), 8.46 (d, ³*J* = 8 Hz, 2H, $H^{3^{\circ},5^{\circ}}$, 2H), 8.40–8.31 (m, H4, $H^{4^{\circ},3^{\circ}a,4^{\circ}a,5^{\circ}a}$), 7.96 (dt, ³*J* = 8 Hz, 2H, $H^{4^{\circ},4^{\circ}}$), 7.47 (dd, ³*J* = 6.4 Hz, 2H, $H^{6^{\circ},6^{\circ}}$), 7.25 (dt, ³*J* = 6.6 Hz, 2H, $H^{5^{\circ},5^{\circ}}$), 4.18 (t, ³*J* = 7.2 Hz, 4H, H^{alkyl}), 1.65 (m_c, 4H, H^{alkyl}), 1.30–0.93 (m, 28H, H^{alkyl}), 0.88 (t, ³*J* = 7.0 Hz, 6H, H^{alkyl}) ppm. ¹³C NMR (100 MHz, CD₃CN): δ = 158.1, 156.5, 152.9, 149.6, 149.3, 138.1, 137.5, 136.1, 127.6, 125.5, 124.0, 122.8, 120.6, 52.1, 31.6, 29.1, 29.0, 28.9, 28.98, 28.3, 25.5, 22.4, 13.4 ppm. MS (MALDI-TOF, dithranol): m/z = 973.46 ([M - PF₆]⁺). Elem. anal. calcd. for C₄₄H₅₈F₁₂N₁₀P₂Ru (1118.00): C, 47.27%; H, 5.23%; N, 12.53%; found: C, 47.46%; H, 5.44%; N, 12.46%. UV-vis (CH₃CN): λ_{max} (ε/L·mol⁻¹·cm⁻¹) = 432 (11,500), 356 (5,500), 303 (39,000), 286 (41,500), 226 (41,500) nm.

 $[(R^2-tpy)Ru(tripy-R^1)](PF_6)_2$ $(R^1 = C_{11}H_{22}OH, R^2 = H)$: [2,6-Bis(11-undecanol-1-yl-1H-1,2,3-triazol-4-yl)pyridine] [2,2':6',2''-terpyridine] ruthenium(II) hexafluorophosphate (2)



Following the general procedure, $(R^2$ -tpy)RuCl₃ ($R^2 = H$,^{2a} 60 mg, 0.14 mmol) and **R¹-tripy** ($R^1 = C_{11}H_{22}OH$, 75 mg, 0.14 mmol) were reacted to yield **2** (144 mg, 90%) as an orange-red solid.

¹H NMR (400 MHz, CD₃CN): δ = 8.66 (d, ³*J* = 8 Hz, 2H, *H*^{3',5'}, 2H), 8.64 (s, 2H, *H*^{5a,5''a}), 8.47 (d, ³*J* = 8 Hz, 2H, *H*^{3,3''}), 8.33 (m_c, 4H, *H*^{4',3'a,4'a,5'a}), 7.96 (dt, ³*J* = 8 Hz, 2H, *H*^{4',4''}), 7.45 (dd, ³*J* = 5.2 Hz, 2H, *H*^{6',6''}), 7.25 (dt, ³*J* = 6.6 Hz, 2H, *H*^{5',5''}), 4.17 (t, ³*J* = 7.0 Hz, 4H, *H*^{alkyl}), 3.48 (m_c, 4H, *H*^{alkyl}), 2.47 (t, ³*J* = 5.2 Hz, 2H, *H*^{OH}), 1.64 (m_c, 4H, *H*^{alkyl}), 1.48 (m_c, 4H, *H*^{alkyl}), 1.35–0.90 (m, 28H, *H*^{alkyl}) ppm. ¹³C NMR (100 MHz, CD₃CN): δ = 158.2, 156.5, 152.8, 149.6, 149.3, 138.1, 137.5, 136.1, 127.5, 125.4, 124.0, 122.8, 120.6, 61.6, 52.1, 32.6, 29.2, 29.1, 29.0, 28.9, 28.8, 28.2, 25.6, 25.4 ppm. MS (MALDI-TOF, dithranol): *m*/*z* = 1033.33 ([M - PF₆]⁺). Elem. anal. calcd. for C₄₆H₆₂F₁₂N₁₀O₂P₂Ru (1178.05): C, 46.90%; H, 5.30%; N, 11.89%; found: C, 46.96%; H, 5.66%; N, 11.82%. UV-vis (CH₂Cl₂): λ_{max} (ε/L·mol⁻¹·cm⁻¹) = 435 (10,000), 356 (4,500), 305 (36,000), 287 (37,500) nm.

 $[(R^{2}-tpy)Ru(tripy-R^{1})](PF_{6})_{2} (R^{1} = C_{10}H_{21}, R^{2} = 4-Br-C_{6}H_{4}): [2,6-Bis(1-decyl-1H-1,2,3-triazol-4-yl)pyridine] [4'-(4-bromophenyl)-2,2':6',2''-terpyridine] ruthenium(II) hexafluorophosphate (3)$



Following the general procedure, $(R^2-tpy)RuCl_3$ ($R^2 = 4$ -Br-C₆H₄,^{2b} 98 mg, 0.16 mmol) and **R¹-tripy** ($R^1 = C_{10}H_{21}$, 81 mg (0.16 mmol) were reacted to yield **3** (111 mg, 53%) as orangered solid after subsequent column chromatography (alumina, CH₂Cl₂/acetone, elution of the product with CH₂Cl₂/methanol, 1:1), gel filtration (silica, CH₃CN, elution of the product with CH₃CN/water 9:1, sat. with KNO₃) and reprecipitation into diethyl ether.

¹H NMR (400 MHz, CD₃CN): δ = 8.86 (s, 2H, *H*^{5a,5''a}), 8.68 (s, 2H, H^{3',5'}), 8.53 (d, ³*J* = 8 Hz, 2H, *H*^{3',3''}), 8.37 (m_c, 3H, *H*^{3'a4'a,5'a}), 8.09 (d, ³*J* = 8.4 Hz, 2H, *H*^{AA'/BB'}), 7.95 (dt, ³*J* = 8 Hz, 2H, *H*^{4',4''}), 7.86 (d, ³*J* = 8.4 Hz, 2H, *H*^{BB'/AA'}), 7.50 (dd, ³*J* = 5.6 Hz, 2H, *H*^{6',6''}), 7.27 (dt, ³*J* = 6.8 Hz, 2H, *H*^{5',5''}), 4.19 (t, ³*J* = 7.2 Hz, 4H, *H*^{alkyl}), 1.66 (m_c, 4H, *H*^{alkyl}), 1.30–0.93 (m, 28H, *H*^{alkyl}), 0.86 (t, ³*J* = 7.0 Hz, 6H, *H*^{alkyl}) ppm. ¹³C NMR (100 MHz, CD₃CN): δ = 158.2, 156.8, 153.0, 149.6, 149.3, 147.1, 138.1, 137.6, 135.7, 132.6, 129.7, 127.6, 125.5, 124.5, 124.2, 120.6, 120.5, 52.1, 31.6, 29.1, 29.0, 28.9, 28.2, 25.5, 22.4, 13.4 ppm. MS (MALDI-TOF, dithranol): *m*/*z* = 1129.05 ([M - PF₆]⁺). Elem. anal. calcd. for C₅₀H₆₁BrF₁₂N₁₀P₂Ru (1272.99): C, 47.18%; H, 4.83%; N, 11%; found: C, 47.11%; H, 4.63%; N, 10.91%. UV-vis (CH₂Cl₂): λ_{max} (ε/L·mol⁻¹·cm⁻¹) = 456 (16,500), 438 (16,000), 356 (6,500), 287 (67,000) nm.

 $[(R^{2}-tpy)Ru(tripy-R^{1})](PF_{6})_{2} (R^{1} = C_{11}H_{22}OH, R^{2} = 4-Br-C_{6}H_{4}): [2,6-Bis(11-undecanol-1-yl-1H-1,2,3-triazol-4-yl)pyridine] [4'-(4-bromophenyl)-2,2':6',2''-terpyridine] ruthenium(II) hexafluorophosphate (4)$



Following the general procedure, (R²-tpy)RuCl₃ (R² = 4-Br-C₆H₄,^{2b} 97 mg, 0.16 mmol) and **R¹-tripy** (R¹ = C₁₁H₂₂OH, 90 mg, 0.16 mmol) were reacted to yield **4** (91 mg, 42%) as an orange-red solid after purification by column chromatography (alumina, CH₂Cl₂/acetone 1:1). ¹H NMR (400 MHz, CD₃CN): δ = 8.89 (s, 2H, $H^{5a,5"a}$), 8.66 (s, 2H, $H^{3",5"}$), 8.59 (d, ³*J* = 8 Hz, 2H, $H^{3",3"}$), 8.35 (m_c, 3H, $H^{3"a,4"a,5"a}$), 8.11 (d, ³*J* = 8.4 Hz, 2H, $H^{AA'/BB'}$), 7.97 (dt, ³*J* = 8 Hz, 2H, $H^{4",4"}$), 7.91 (d, ³*J* = 8.4 Hz, 2H, $H^{BB'/AA'}$), 7.48 (dd, ³*J* = 5.6 Hz, 2H, $H^{6",6"}$), 7.26 (dt, ³*J* = 6.8 Hz, 2H, $H^{5",5"}$), 4.18 (t, ³*J* = 7.0 Hz, 4H, H^{alkyl}), 3.47 (m_c, 4H, H^{alkyl}), 2.47 (t, ³*J* = 5.4 Hz, 2H, H^{OH}), 1.65 (m_c, 4H, H^{alkyl}), 1.45 (m_c, 4H, H^{alkyl}), 1.34–0.91 (m, 28H, H^{alkyl}) ppm. ¹³C NMR (100 MHz, CD₃CN): δ = 158.2, 156.8, 153.0, 149.6, 149.3, 147.1, 138.1, 137.6, 135.7, 132.6, 129.7, 127.6, 125.5, 124.5, 124.2, 120.6, 120.5, 61.6, 52.1, 32.6, 29.2, 29.1, 29.0, 28.9, 28.2, 25.6, 25.4 ppm. MS (MALDI-TOF, dithranol): *m/z* = 1187.14 ([M -

 $PF_6]^+$). Elem. anal. calcd. for $C_{52}H_{65}BrF_{12}N_{10}O_2P_2Ru$ (1333.04): C, 46.85%; H, 4.91%; N, 10.51%; found: C, 46.63%; H, 4.99%; N, 10.54%. UV-vis (CH₂Cl₂): λ_{max} ($\epsilon/L \cdot mol^{-1} \cdot cm^{-1}$) = 456 (16,500), 438 (16,000), 356 (6,500), 287 (67,000) nm.

 $[(R^{2}-tpy)Ru(tripy-R^{1})](PF_{6})_{2} (R^{1} = 4-MeO-C_{6}H_{4}, R^{2} = 4-Br-C_{6}H_{4}): [2,6-Bis(1-(4-methoxyphenyl)-1H-1,2,3-triazol-4-yl)pyridine] [4'-(4-bromophenyl)-2,2':6',2''-terpyridine] ruthenium(II) hexafluorophosphate (5)$



Following the general procedure, $(R^2$ -tpy)RuCl₃ ($R^2 = 4$ -Br-C₆H₄,^{2b} 135 mg, 0.23 mmol) and **R¹-tripy** ($R^1 = 4$ -MeO-C₆H₄, 100 mg, 0.23 mmol) were reacted to yield **5** (145 mg, 53%) as an orange-red solid after purification by column chromatography (silica, CH₃CN/water 9:1, sat. with KNO₃). Single crystals were obtained by slow diffusion of diethyl ether into a concentrated solution of **5** in CH₃CN.

¹H NMR (400 MHz, CD₃CN): δ = 9.08 (s, 2H, *H*^{5a,5''a}), 8.92 (s, 2H, *H*^{3',5'}), 8.62 (d, ³*J* = 8.0 Hz, 2H, *H*^{3',3''}), 8.43 (m_c, 3H, *H*^{3'a,4'a,5'a}), 8.12 (d, ³*J* = 8.4 Hz, 2H, *H*^{AA'/BB'}), 8.02 (dt, ³*J* = 8.0 Hz, 2H, *H*^{4',4''}), 7.93 (d, ³*J* = 8.4 Hz, 2H, *H*^{BB'/AA'}), 7.57 (dd, ³*J* = 5.6 Hz, 2H, *H*^{6',6''}), 7.44 (d, ³*J* = 9.2 Hz, 2H, *H*^{CC'/DD'}), 7.30 (dt, ³*J* = 6.4 Hz, 2H, *H*^{5',5''}), 7.02 (d, ³*J* = 9.2 Hz, 2H, *H*^{DD'/CC'}), 3.80 (s, 3H, *H*^{methoxy}) ppm. ¹³C NMR (100 MHz, CD₃CN): δ = 160.8, 158.3, 156.8, 153.2, 150.0, 149.5, 147.4, 138.2, 137.8, 135.9, 132.6, 129.7, 129.1, 127.6, 124.4, 124.3, 123.6, 122.4, 120.9, 120.8, 114.9, 55.5 ppm. MS (MALDI-TOF, dithranol): *m*/*z* = 1061.34 ([M - PF₆]⁺). Elem. anal. calcd. for C₄₄H₃₃BrF₁₂N₁₀O₂P₂Ru (1204.70): C, 43.87%; H, 2.76%; N, 11.63%; found: C, 44.03%; H, 2.84%; N, 11.53%. UV-vis (CH₂Cl₂): λ_{max} (ε/L·mol⁻¹·cm⁻¹) = 456 (14,500), 435 (13,500), 300 (73,000) nm.

 $[(R^{2}-tpy)Ru(tripy-R^{1})](PF_{6})_{2} (R^{1} = 4^{t}Bu-C_{6}H_{4}-CH_{2}, R^{2} = 4-Br-C_{6}H_{4}): [2,6-Bis(1-(4^{t}butyl-benzyl)-1H-1,2,3-triazol-4-yl)pyridine] [4'-(4-bromophenyl)-2,2':6',2''-terpyridine] ruthenium(II) hexafluorophosphate (6)$



Following the general procedure, $(R^2-tpy)RuCl_3$ ($R^2 = 4-Br-C_6H_4$,^{2b} 106 mg, 0.18 mmol), **R**¹**tripy** ($R^1 = 4-{}^tBu-C_6H_4-CH_2$, 90 mg, 0.18 mmol) were reacted to yield **6** as an orange-red solid (66 mg, 28%) after purification by column chromatography (silica, CH₃CN/H₂0 9:1, saturated with KNO₃).

¹H NMR (400 MHz, CD₃CN): $\delta = 8.75$ (s, 2H, $H^{5a,5"a}$), 8.57 (s, 2H, $H^{3'a,5'a}$), 8.38 (m, 3H, $H^{3',5',4'a}$), 8.12 (d, ${}^{3}J = 8.0$ Hz, 2H, $H^{3,3"}$), 7.81 (d, ${}^{3}J = 8$ Hz, 2H, $H^{AA'/BB'}$), 7.77 (dt, ${}^{3}J = 8.0$ Hz, 2H, $H^{4,4"}$), 7.62 (d, ${}^{3}J = 8$ Hz, 2H, $H^{BB'/AA'}$), 7.48 (dd, ${}^{3}J = 5.6$ Hz, 2H, $H^{6,6"}$), 7.23 (dt, ${}^{3}J = 6.8$ Hz, 2H, $H^{5,5"}$), 7.19 (d, ${}^{3}J = 8$ Hz, 4H, $H^{CC'/DD'}$), 6.98 (d, ${}^{3}J = 8$ Hz, 4H, $H^{DD'/CC'}$), 5.36 (s, 2H, CH₂), 1.11 (s, 18H, CH₃) ppm. ¹³C NMR (100 MHz, CD₃CN): $\delta = 157.8$, 156.8, 153.2, 152.1, 149.7, 149.5, 146.3, 138.1, 137.7, 134.7, 132.6, 130.4, 129.1, 128.1, 127.6, 126.0, 125.9, 124.7, 123.8, 121.0, 119.7, ~55 (with solvent), 34.1, 30.3 ppm. MS (MALDI-TOF, dithranol): m/z = 1139.17 ([M - PF₆]⁺). Elem. anal. calcd. for C₅₂H₄₉BrF₁₂N₁₀P₂Ru (1284.92): C, 48.61%; H, 3.84%; N, 10.9%; found: C, 48.4%; H, 4.13%; N, 10.82%. UV-vis (CH₂Cl₂): λ_{max} (ε/L·mol⁻¹·cm⁻¹) = 455 (17,500), 435 (16,500), 357 (6,000), 288 (73,000) nm.

 $[(R^{1}-tripy)Ru(tripy-R^{1'})](PF_{6})_{2} (R^{1} = C_{10}H_{21}, R^{1'} = C_{11}H_{22}OH): [2,6-Bis(11-undecanol-1-yl-1H-1,2,3-triazol-4-yl)pyridine] [2,6-bis(1-decyl-1H-1,2,3-triazol-4-yl)pyridine] ruthenium(II) hexafluorophosphate (6)$



A suspension of RuCl₃ × H₂O (57 mg, 0.2 mmol) and **R**¹-tripy (R¹ = C₁₀H₂₁, 100 mg, 0.2 mmol) in methanol (40 mL) was refluxed till TLC monitoring indicated the full consumption of the ligand. After 20 h, **R**^{1'}-tripy (R^{1'} = C₁₁H₂₂OH, 112 mg, 0.2 mmol) and *N*-ethyl morpholine (5 drops) were added and the reaction mixture was refluxed till TLC monitoring indicated also the consumption of the second ligand. After 3 days, the reaction mixture was purified (see General Procedure above) by column chromatography (silica, CH₃CN/water 95:5, sat. with KNO₃) yielding **6** (165 mg, 57%).

¹H NMR (400 MHz, CD₃CN): δ = 8.67 (s, 4H, *H*^{5,5''}), 8.26 (m_c, 6H, *H*^{3',4',5'}), 4.23 (t, ³*J* = 7.2 Hz, 8H, *H*^{alkyl}), 3.49 (t, ³*J* = 6.4 Hz, 4H, *H*^{alkyl}), 2.51 (s, 1H, *H*^{OH}), 1.70 (m_c, 8H, *H*^{alkyl}), 1.47 (m_c, 4H, *H*^{alkyl}), 1.30–1.00 (m, 56H, *H*^{alkyl}), 0.89 (t, ³*J* = 7.2 Hz, 6H, *H*^{alkyl}) ppm. ¹³C NMR (100 MHz, CD₃CN): δ = 150.7, 149.4, 137.8, 125.2, 119.8, 61.6, 52.1, 32.6, 31.6, 29.3, 29.2, 29.1, 29.00, 28.4, 28.3, 25.7, 25.6, 22.4, 13.4 ppm. MS (MALDI-TOF, dithranol): *m/z* = 1293.61 ([M - PF₆]⁺). Elem. anal. calcd. for C₆₀H₉₈F₁₂N₁₄O₂P₂Ru (1438.51): C, 50.10%; H, 6.87%; N, 13.63%; found: C, 50.28%; H, 7.09%; N, 13.37%. UV-vis (CH₂Cl₂): λ_{max} (ε/L·mol⁻¹·cm⁻¹) = 395 (18,000), 286 (63,000), 256 (32,500) nm.

X-Ray crystallographic data

Crystal structure determination

The intensity data for the compound were collected with a Nonius KappaCCD diffractometer, using graphite-monochromated Mo-K_{α} radiation. The data were corrected for Lorentz and polarization effects, but not for absorption effects.^{5,6} The structure was solved by direct methods (SHELXS⁷) and refined by full-matrix least squares techniques against Fo² (SHELXL-97⁸). The hydrogen atoms were included at calculated positions with fixed thermal parameters. All non-hydrogen atoms were refined anisotropically. XP (SIEMENS Analytical X-ray Instruments, Inc.) was used for structure representations. CCDC-691377 contains the supplementary crystallographic data for **5**. The data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: (+44) 1223-336-033; deposit@ccdc.cam.ac.uk/.

$[(R^{2}-tpy)Ru(tripy-R^{1})](PF_{6})_{2} (R^{1} = 4-MeO-C_{6}H_{4}, R^{2} = 4-Br-C_{6}H_{4}) (5)$

Empirical formula: $C_{44}H_{22}BrN_{10}O_{2}Ru_{2}(E_{2}P)_{2}(C_{2}H_{2}N)$

Empirical formation	(-241133D111002Ru 2(161)2(-211311))
Color of crystal:	red-brown prism
Crystal system:	triclinic
Space group:	Pī
Crystal size:	$0.05 \times 0.04 \times 0.04 \text{ mm}^3$
Data:	μ (Mo-K _{α}) = 12.2 cm ⁻¹ , T = 183 K, F(000) = 1288, 18915 reflections in
	h(-13/13), k(-20/17), l(-20/21), measured in the range $1.65^{\circ} \le \Theta \le 27.48^{\circ}$,
	completeness $\Theta_{\text{max}} = 98.2\%$,11802 independent reflections, $R_{\text{int}} = 0.0474$,
	8528 reflections with $F_o > 4\sigma(F_o)$, 707 parameters, 0 restraints, $R1_{obs} =$
	0.0632, wR ² _{obs} = 0.1407, R1 _{all} = 0.0984, wR ² _{all} = 0.1576, GOOF = 1.077,
	largest difference peak and hole: 1.338 / -1.225 e Å ⁻³

⁵ COLLECT, Data Collection Software, Nonius B.V., the Netherlands, **1998**.

⁶ Z. Otwinowski, W. Minor, *Processing of X-Ray Diffraction Data Collected in Oscillation Mode* in *Methods in Enzymology*, Vol. 276, *Macromolecular Crystallography, Part A*, ed. C. W. Carter, R. M. Sweet, pp. 307–326, Academic Press **1997**.

⁷ G. M. Sheldrick, Acta Crystallogr., Sect. A 1990, 46, 467.

⁸ G. M. Sheldrick, SHELXL-97 (release 97-2), University of Göttingen, Germany, **1997**.

Cell dimensions:
$$a = 10.4011(4) \text{ Å}$$

 $b = 15.6521(7) \text{ Å}$
 $c = 16.4051(6) \text{ Å}$
 $\alpha = 101.112(2)^{\circ}$
 $\beta = 93.416(3)^{\circ}$
 $\gamma = 90.460(2)^{\circ}$
Molecules/cell: $Z = 2$
Volume: $V = 2615.49(18) \text{ Å}^{3}$
Calculated density: $\rho_{calcd.} = 1.634 \text{ g} \cdot \text{cm}^{-3}$
Molecular weight: $M_r = 1286.83 \text{ g} \cdot \text{mol}^{-1}$



Figure 1. Schematic representation of the X-ray crystal structure of 5, including the PF_6^- counterion and the coordinated CH₃CN molecules.

¹H and ¹³C NMR spectra



Figure 2. ¹H NMR spectrum (400 MHz, CD_2Cl_2) of **R**¹-tripy (R¹ = $C_{10}H_{21}$).



Figure 3. ¹³C NMR spectrum (100 MHz, CD_2Cl_2) of **R**¹-tripy (R¹ = $C_{10}H_{21}$).



Figure 4. ¹H NMR spectrum (400 MHz, CD_2Cl_2) of **R**¹-tripy (R¹ = C₁₁H₂₂OH).



Figure 5. ¹³C NMR spectrum (100 MHz, CDCl₃) of \mathbf{R}^1 -tripy ($\mathbf{R}^1 = C_{11}H_{22}OH$).



Figure 6. ¹H NMR spectrum (400 MHz, CD_2Cl_2) of **R**¹-tripy (R¹ = C₈H₁₆CH=CH₂).



Figure 7. ¹³C NMR spectrum (100 MHz, CDCl₃) of \mathbf{R}^1 -tripy ($\mathbf{R}^1 = \mathbf{C}_8\mathbf{H}_{16}\mathbf{CH}=\mathbf{CH}_2$).



Figure 8. ¹H NMR spectrum (400 MHz, CD_2Cl_2) of **R**¹-tripy (R¹ = 4-^{*t*}Bu-C₆H₄-CH₂).



Figure 9. ¹³C NMR spectrum (100 MHz, CDCl₃) of \mathbf{R}^1 -tripy ($\mathbf{R}^1 = 4$ -^{*t*}Bu-C₆H₄-CH₂).



Figure 10. ¹H NMR spectrum (400 MHz, CDCl₃) of \mathbf{R}^{1} -tripy (\mathbf{R}^{1} = 4-MeO-C₆H₄).



Figure 11. ¹³C NMR spectrum (100 MHz, CDCl₃) of \mathbf{R}^{1} -tripy (\mathbf{R}^{1} = 4-MeO-C₆H₄).



Figure 12. ¹H NMR spectrum (400 MHz, CDCl₃) of \mathbf{R}^{1} -tripy (\mathbf{R}^{1} = naphth-1-yl).



Figure 13. ¹³C NMR spectrum (100 MHz, CDCl₃) of \mathbf{R}^{1} -tripy (\mathbf{R}^{1} = naphth-1-yl).

Figure 14. ¹H NMR spectrum (400 MHz, d₆-acetone) of 9.

Figure 15. ¹³C NMR spectrum (100 MHz, CD₃CN) of 9.

Figure 16. ¹H NMR spectrum (400 MHz, CD₃CN) of 1.

Figure 17. ¹³C NMR spectrum (100 MHz, CD₃CN) of 1.

Figure 18. ¹H NMR spectrum (400 MHz, CD₃CN) of 2.

Figure 19. ¹³C NMR spectrum (100 MHz, CD₃CN) of 2.

Figure 20. ¹H NMR spectrum (400 MHz, CD₃CN) of 3.

Figure 21. ¹³C NMR spectrum (100 MHz, CD₃CN) of 3.

Figure 22. ¹H NMR spectrum (400 MHz, CD₃CN) of 4.

Figure 23. ¹³C NMR spectrum (100 MHz, CD₃CN) of 4.

Figure 24. ¹H NMR spectrum (400 MHz, CD₃CN) of 5.

Figure 25. ¹³C NMR spectrum (100 MHz, CD₃CN) of 5.

Figure 26. ¹H NMR spectrum (400 MHz, CD₃CN) of 6.

Figure 27. ¹³C NMR spectrum (100 MHz, CD₃CN) of 6.

Figure 28. ¹H NMR spectrum (400 MHz, CD₃CN) of 7.

Figure 29. ¹³C NMR spectrum (100 MHz, CD₃CN) of 7.

¹H-¹H gCOSY NMR spectra

Figure 30. ¹H-¹H gCOSY NMR spectrum (400 MHz, CD₃CN) of 1.

400 MHz, solvent: acetonitrile-d3

Figure 31. ¹H-¹H gCOSY NMR spectrum (400 MHz, CD₃CN) of 2.

Figure 32. ¹H-¹H gCOSY NMR spectrum (400 MHz, CD₃CN) of 3.

Figure 33. ¹H-¹H gCOSY NMR spectrum (400 MHz, CD₃CN) of 4.

Figure 34. ¹H-¹H gCOSY NMR spectrum (400 MHz, CD₃CN) of 6.

Figure 35. MALDI-TOF mass spectrum (dithranol as matrix) of \mathbf{R}^1 -tripy ($\mathbf{R}^1 = C_{10}H_{21}$).

Figure 36. MALDI-TOF mass spectrum (dithranol as matrix) of \mathbf{R}^{1} -tripy ($\mathbf{R}^{1} = \mathbf{C}_{12}\mathbf{H}_{22}\mathbf{OH}$).

Figure 37. MALDI-TOF mass spectrum (dithranol as matrix) of \mathbf{R}^1 -tripy ($\mathbf{R}^1 = C_8 H_{16} C = C H_2$).

Figure 38. MALDI-TOF mass spectrum (dithranol as matrix) of \mathbf{R}^{1} -tripy ($\mathbf{R}^{1} = 4$ -^{*t*}Bu-C₆H₄-CH₂).

Figure 39. MALDI-TOF mass spectrum (dithranol as matrix) of \mathbf{R}^{1} -tripy (\mathbf{R}^{1} = 4-MeO-C₆H₄).

Figure 40. MALDI-TOF mass spectrum (dithranol as matrix) of \mathbf{R}^{1} -tripy (\mathbf{R}^{1} = naphth-1-yl).

Figure 41. MALDI-TOF mass spectrum (dithranol as matrix) of 9.

Figure 42. MALDI-TOF mass spectrum (dithranol as matrix) of 1.

Figure 43. MALDI-TOF mass spectrum (dithranol as matrix) of 2.

Figure 44. MALDI-TOF mass spectrum (dithranol as matrix) of 3.

Figure 45. MALDI-TOF mass spectrum (dithranol as matrix) of 4.

Figure 46. MALDI-TOF mass spectrum (dithranol as matrix) of 5.

Figure 47. MALDI-TOF mass spectrum (dithranol as matrix) of 6.

Figure 48. MALDI-TOF mass spectrum (dithranol as matrix) of 7.